Back to search
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti…